BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)
ALAMEDA, Calif.--(BUSINESS WIRE)--May 23, 2017--
BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage
biotechnology company developing and commercializing products addressing
degenerative diseases, today announced that BioTime, and its subsidiary
Cell Cure Neurosciences Ltd., will be featured in two presentations at
the 16th National Life Sciences and Biotechnology Week
(MIXiii BIOMED) on Wednesday, May 24, 2017 as part of the Regenerative
and Cell Therapies track. The conference is being held at the David
InterContinental in Tel Aviv, Israel, May 23-25, 2017.
Presentations will be held at 12:15 p.m. and 3:45 p.m. IDT in Hall B of
the InterContinental, and will highlight both the company’s technology
and business model. Jim Knight, BioTime, Inc. Senior Vice President and
Head of Corporate Development, will discuss the evolution of the BioTime
group of companies during one of the presentations. A second
presentation will focus on cell-based transplantation therapy in AMD
patients. Each presentation will be followed by a panel discussion. More
information about the conference program and presentations can be found here.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what the
company believes to be the world’s premier collection of pluripotent
cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products. BioTime also
has significant equity holdings in two publicly traded companies,
Asterias Biotherapeutics, Inc. and OncoCyte Corporation, which BioTime
founded and which, until recently, were majority-owned consolidated
subsidiaries of BioTime.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com or
connect with the company on Twitter,
View source version on businesswire.com: http://www.businesswire.com/news/home/20170523005380/en/
Source: BioTime, Inc.
EVC Group, Inc.
Michael Polyviou/Doug Sherk,
JQA Partners, Inc.
Jules Abraham, 917-885-7378